Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Linke

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Onkologie|November 10, 2007
Management of imatinib-resistant CML patientsRolf Linke, Wolfram Dempke
Mabs|March 2, 2010
Catumaxomab: clinical development and future directionsRolf Linke, Anke Klein, Diane Seimetz
Melanoma Research|February 2, 2013
The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costsCarolina Reyes, Stacey DaCosta Byfield, Rolf Linke, et al.
International Journal of Cancer|June 25, 2011
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascitesMarion G Ott, Frederik Marmé, Gerhard Moldenhauer, et al.
Future Oncology (London, England)|July 18, 2019
Effects of dose modifications on the safety and efficacy of dacomitinib for <i>EGFR</i> mutation-positive non-small-cell lung cancerJesús Corral, Tony S Mok, Kazuhiko Nakagawa, et al.
Future Oncology (London, England)|November 9, 2020
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050Jean Paty, Rickard Sandin, Arlene Reisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating MutationsTony S Mok, Ying Cheng, Xiangdong Zhou, et al.
The Lancet. Oncology|September 30, 2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi-Long Wu, Ying Cheng, Xiangdong Zhou, et al.
Future Oncology (London, England)|October 3, 2024
Efficacy in patients with <i>EGFR</i>-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: <i>post hoc</i> analyses from ARCHER 1050Xingxiang Pu, Juan Li, Bo Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)Ying Cheng, Tony S Mok, Xiangdong Zhou, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Onkologie|November 10, 2007
Management of imatinib-resistant CML patientsRolf Linke, Wolfram Dempke
Mabs|March 2, 2010
Catumaxomab: clinical development and future directionsRolf Linke, Anke Klein, Diane Seimetz
Melanoma Research|February 2, 2013
The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costsCarolina Reyes, Stacey DaCosta Byfield, Rolf Linke, et al.
International Journal of Cancer|June 25, 2011
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascitesMarion G Ott, Frederik Marmé, Gerhard Moldenhauer, et al.
Future Oncology (London, England)|July 18, 2019
Effects of dose modifications on the safety and efficacy of dacomitinib for <i>EGFR</i> mutation-positive non-small-cell lung cancerJesús Corral, Tony S Mok, Kazuhiko Nakagawa, et al.
Future Oncology (London, England)|November 9, 2020
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050Jean Paty, Rickard Sandin, Arlene Reisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating MutationsTony S Mok, Ying Cheng, Xiangdong Zhou, et al.
The Lancet. Oncology|September 30, 2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi-Long Wu, Ying Cheng, Xiangdong Zhou, et al.
Future Oncology (London, England)|October 3, 2024
Efficacy in patients with <i>EGFR</i>-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: <i>post hoc</i> analyses from ARCHER 1050Xingxiang Pu, Juan Li, Bo Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)Ying Cheng, Tony S Mok, Xiangdong Zhou, et al.
Pageof 2